Issue |
Section |
Title |
File |
No 3 (2011) |
Articles |
OPTIMIZATION OF ANTIRESORPTIVE THERAPY WITH BISPHOSPHONATES |
|
No 5 (2012) |
Articles |
THE CLINICAL AND PROGNOSTIC VALUE OF HYPOVITAMINOSIS D IN POSTMENOPAUSAL OSTEOPOROSIS |
|
No 11 (2013) |
Articles |
PATHOGENETIC BASES FOR THE DEVELOPMENT OF AN ACUTE PHASE RESPONSE TO INTRAVENOUS ADMINISTRATION OF NITROGEN-CONTAINING BISPHOSPHONATES |
|
No 2 (2014) |
Articles |
Vaginal atrophy |
|
No 3 (2014) |
Articles |
FEMALE REPRODUCTIVE SYSTEM AGING: FROM THEORY TO CLINICAL PRACTICE PART 1. THE ENDOCRINE AND CLINICAL CHARACTERISTICS OF FEMALE REPRODUCTIVE SYSTEM AGING STAGES |
|
No 4 (2014) |
Articles |
Female reproductive system aging: From theory to clinical practice. Part 2. Role of hormone therapy in solving the problems of transition stage and early postmenopause |
|
No 8 (2014) |
Articles |
Non-instrumental screening for low bone mineral density in women with secondary amenorrhea |
|
No 11 (2014) |
Articles |
Prevalence of vulvovaginal atrophy and its impact on quality of life in women. The issues of terminology and the safety of local hormone therapy |
|
No 6 (2015) |
Articles |
OPTIMIZATION OF MENOPAUSAL HORMONE THERAPY-RELATED RISKS: THERAPY WITH TRANSDERMAL ESTROGENS ALONE OR IN COMBINATION WITH MICRONIZED PROGESTERONE. ADVANTAGES AGAINST METABOLIC RISKS AND ARTERIAL THROMBOSIS |
|
No 5 (2015) |
Articles |
OPTIMIZATION OF MENOPAUSAL HORMONE THERAPY-RELATED RISKS: MONOTHERAPY WITH TRANSDERMAL ESTROGENS OR IN COMBINATION WITH MICRONIZED PROGESTERONE. ADVANTAGES AGAINST VENOUS THROMBOEMBOLISM AND BREAST CANCER |
|
No 12 (2015) |
Articles |
VULVOVAGINAL ATROPHY: SYMPTOMS, IMPACT ON EMOTIONAL WELL-BEING, QUALITY, AND SEXUAL FUNCTION |
|
No 6 (2016) |
Articles |
Alternative methods for the treatment of vasomotor symptoms in postmenopausal women |
|
No 5 (2016) |
Articles |
GENITOURINARY SYNDROME OF MENOPAUSE IN PERI- AND POSTMENOPAUSAL PATIENTS: DIAGNOSIS AND THERAPY (short clinical guidelines) |
|
No 9 (2016) |
Articles |
VENOUS THROMBOEMBOLISM AND COMBINED ORAL CONTRACEPTION |
|
No 3 (2017) |
Articles |
Menopausal hormone therapy and risk of coronary heart disease |
|
No 8 (2017) |
Articles |
Role of hypothalamic (trigger) neuropeptides in the genesis of hot flushes. Prospects for new therapeutic approaches to treating vasomotor menopausal symptoms |
|
No 11 (2017) |
Articles |
Menopausal hormone therapy and cervical cancer: A current view of the problem |
|
No 4 (2018) |
Articles |
Characteristics of risk factors for dementia in women: a possible preventive role of menopausal hormone therapy |
|
No 6 (2018) |
Articles |
Evolution of the goals of menopausal hormone therapy. From treatment for hot flushes to the new horizons of cardiometabolic protection |
|
No 1 (2019) |
Articles |
Menopausal vasomotor symptoms: social aspects, dynamics, cardiometabolic risks, hormone therapy options |
|
No 5 (2019) |
Articles |
Menopause, obesity, and comorbidity: possibilities of menopausal hormone therapy |
|
No 11 (2019) |
Articles |
Relationship between the symptoms of vulvovaginal epithelial atrophy and the vaginal microbiota in postmenopausal women |
|
No 11 (2019) |
Articles |
The role of neurokinin B in the pathophysiological mechanisms of vasomotor symptoms and sleep disturbances in postmenopausal women |
|
No 2 (2020) |
Articles |
Weight gain in perimenopausal women: methods for assessing the body composition and maintenance tactics |
|
No 2 (2020) |
Articles |
Management of menopausal women with a history of endometriosis |
|
No 3 (2020) |
Articles |
Risk and benefits of menopausal hormonal therapy |
|
No 12 (2020) |
Articles |
The role of lipids determined by a mass spectrometry method in the development of cardiometabolic diseases in menopausal women |
|
No 6 (2021) |
Articles |
Surgical menopause as a risk factor for the early development of comorbid conditions in reproductive-aged women |
|
No 9 (2021) |
Articles |
Menopausal hormone therapy for rheumatic diseases (gout) |
|
No 12 (2021) |
Articles |
Menopausal hormone therapy for rheumatic diseases: osteoarthritis |
|
No 8 (2022) |
Articles |
Impact of menopausal hormone therapy on the development and progression of cervical and endometrial cancers |
|
No 11 (2021) |
Articles |
Evaluation of patients’ satisfaction with Angeliq Micro in real clinical practice after 13 cycles of treatment in Russia |
|
No 10 (2022) |
Articles |
Analysis of treatment satisfaction in patients with premature ovarian failure |
|
No 6 (2022) |
Articles |
Changes in serum lipid profile during the menopausal transition |
|
No 11 (2022) |
Articles |
Contraception in cancer survivors: Breast and gynecological cancers (Part I) |
|
No 12 (2022) |
Articles |
Contraception in patients with a history of cancer: skin, gastrointestinal, hematological, and endocrine cancers (Part II) |
|
No 11 (2022) |
Articles |
Pathogenic variants in the BRCA 1 and BRCA2 genes: what is important for a practicing gynecologist to know |
|
No 2 (2022) |
Articles |
Diagnostic value of anthropometric characteristics of obesity in women during the menopause transition |
|
No 10 (2016) |
Articles |
POSSIBILITIES OF LOW-DOSE LOCAL ESTRIOL THERAPY IN POSTMENOPAUSAL WOMEN WITH VULVOVAGINAL ATROPHY |
|
No 6 (2017) |
Articles |
THERAPY FOR VULVOVAGINAL ATROPHY IN POSTMENOPAUSAL WOMEN: CLINICAL AND PATHOGENETIC ASPECTS |
|
No 4 (2023) |
Reviews |
Impact of hormone therapy on the overall and relapse-free survival of patients receiving treatment for ovarian cancer |
|
No 4 (2023) |
Original Articles |
Impact of menopausal hormone therapy on immune system parameters |
|
No 5 (2023) |
Original Articles |
Quality of life in patients with premature ovarian insufficiency treated with hormone replacement therapy |
|
No 6 (2023) |
Reviews |
Impact of systemic menopausal hormone therapy on symptoms of urinary incontinence in postmenopausal women |
|
No 8 (2023) |
Clinical Notes |
Resolution of the Council of Experts in obstetrics-gynecology, dermatovenerology, gastroenterology and microbiology "Principles of intimate hygiene in healthy women and in vulvar diseases" |
|
No 11 (2023) |
Clinical Notes |
Russian eligibility criteria for menopausal hormone therapy in patients with cardiovascular and metabolic diseases |
|